Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Share-based Compensation: 2015-2025

Historic Share-based Compensation for Wave Life Sciences (WVE) over the last 11 years, with Sep 2025 value amounting to $6.5 million.

  • Wave Life Sciences' Share-based Compensation rose 83.29% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 70.34%. This contributed to the annual value of $13.1 million for FY2024, which is 34.16% up from last year.
  • Latest data reveals that Wave Life Sciences reported Share-based Compensation of $6.5 million as of Q3 2025, which was up 4.45% from $6.2 million recorded in Q2 2025.
  • Wave Life Sciences' 5-year Share-based Compensation high stood at $7.0 million for Q2 2022, and its period low was $2.3 million during Q3 2023.
  • In the last 3 years, Wave Life Sciences' Share-based Compensation had a median value of $3.2 million in 2024 and averaged $3.7 million.
  • As far as peak fluctuations go, Wave Life Sciences' Share-based Compensation surged by 155.33% in 2022, and later tumbled by 65.34% in 2023.
  • Wave Life Sciences' Share-based Compensation (Quarterly) stood at $3.7 million in 2021, then declined by 21.98% to $2.9 million in 2022, then declined by 19.09% to $2.4 million in 2023, then spiked by 37.93% to $3.2 million in 2024, then surged by 83.29% to $6.5 million in 2025.
  • Its Share-based Compensation stands at $6.5 million for Q3 2025, versus $6.2 million for Q2 2025 and $5.0 million for Q1 2025.